Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 24, 2025 07:30 ET | Source: Alumis Inc.

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Completes Patient Enrollment in Global LUMUS Phase 2b Trial of ESK-001, Next-Generation Oral TYK2 Inhibitor for SLE, data in 3Q 2026
July 14, 2025 16:05 ET | Source: Alumis Inc.

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
May 29, 2025 07:55 ET | Source: Alumis Inc.

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis
May 14, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
May 13, 2025 13:00 ET | Source: Alumis Inc.

Alumis Stockholders Approve Merger with ACELYRIN

Alumis Stockholders Approve Merger with ACELYRIN
March 25, 2025 02:30 ET | Source: Alumis Inc.

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan
March 19, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
March 10, 2025 08:00 ET | Source: Alumis Inc.

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Alumis to Present at Leerink's 2025 Global Healthcare Conference
March 08, 2025 09:00 ET | Source: Alumis Inc.

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025
February 28, 2025 09:08 ET | Source: Alumis Inc.

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026

Next Page keyboard_arrow_right